ArisGlobal AI launch (XDI, NavaX) could streamline pharmacovigilance and regulatory work for Anavex Life Sciences

Madrid launch spotlights AI tools that could reshape biotech operations

MADRID, Feb 11 (Reuters) — ArisGlobal unveils a suite of AI products that pharmaceutical sponsors and small biotechs can use to speed pharmacovigilance and regulatory workflows. The package — a system‑agnostic data intelligence cortex called XDI, three new NavaX Agents and NavaX Translation — is designed to unify evidence and provide explainable, governed AI across Safety, Regulatory, Clinical and other functions.

Implications for Anavex Life Sciences' PV and regulatory operations

For Anavex Life Sciences, a clinical‑stage biotech focused on neurology, the ArisGlobal releases present immediate operational implications. XDI promises a single, system‑agnostic layer that pulls data across safety databases, clinical systems and regulatory submissions, helping small sponsors align context and intent across teams and reduce interpretive drift when assessing adverse events or labeling changes. That alignment can shorten time to decision on safety signals and ensure traceability for audits — a crucial need for companies with limited internal regulatory resources.

The expanded NavaX Agents specifically target tasks that consume time at biotechs like Anavex. Intelligence Agents translate evolving regulatory guidance into precise rule checklists and assess submission dossiers with compliance evaluations, justifications and confidence scores, potentially improving submission quality and reducing rework. Distribution Agents continuously validate new guidance against internal distribution logic and trigger governed change workflows when discrepancies arise, helping maintain up‑to‑date labeling and distribution controls. Signals Agents act as an active intelligence partner that interprets user intent, selects analytical approaches and orchestrates cross‑functional workflows, which can cut manual review cycles and coordinate safety, clinical and regulatory teams during signal investigations.

Operational gains and compliance reassurance

NavaX Translation, built with TransPerfect Life Sciences, embeds certified translation into PV case intake by routing non‑English forms to pharma‑trained models and linguists and returning translated records via API into LifeSphere. ArisGlobal says this reduces average translation handling from roughly five hours per case to under a minute, a change that particularly benefits global trials and post‑marketing safety surveillance conducted by smaller sponsors.

Together, the products emphasize explainable AI and evidential alignment, offering audit‑ready records, governed traceability and quantified confidence scores. For Anavex and similar firms, the promise is faster, more consistent safety and regulatory decision‑making with less manual overhead and clearer governance for enterprise AI adoption.